In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Clinical advisory meeting held in preparation for COM701 clinical studies anticipated to begin next year
New data show that CAR-T NKR-2 cells can challenge established pancreatic cancer xenografts in humanized mouse models
July saw biotechnology company BioNTech AG share Phase 1 trial results for IVAC MUTANOME, an individualized RNA vaccine based on patient-specific mutations.
New Avant Diagnostics CEO wants to integrate precision diagnostics to treatment
Genoptix and Bionano to use Saphyr System to develop hematologic cancer diagnostics
Cancer Genetics launches companion diagnostic; Illumina announces NGS kit for CDx
HalioDx is now compliant under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for its Marseille-based full-service reference laboratory.
NCCU finds home for orphan diabetes drugs in the prevention of breast cancer
Looking at glycobiology with relation to cancer, plus more in recent oncology R&D news
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.